The Body: The Complete HIV/AIDS Resource Follow Us Follow Us on Facebook Follow Us on Twitter 
Professionals >> Visit The Body PROThe Body en Espanol
HIV/AIDS Resource Center for Women
Michelle Lopez Alora Gale Precious Jackson Nina Martinez Gracia Violeta Ross Quiroga Loreen Willenberg  
Michelle Alora Precious Nina Gracia Loreen  

A Timeline of Women Living With HIV: Past, Present and Future -- 2009

June 2012

2009. An increase in the number of HIV cases among women older than age 50 in Brazil has led the government of Brazil to launch a new prevention campaign promoting empowerment through insistence on condom use. The slogan of the campaign -- "Sex has no age limit. Neither does protection" -- appears on radio, television, and print advertisements.

A new study published in the Journal of Clinical Oncology finds that HIV-positive women and those at risk of acquiring the virus are more likely to develop lung cancer compared to women in the general population.

AIDS diarist Thembi Ngubane dies June 5 at the age of 24. For a little more than a year -- from October 2004 to December 2005 -- Thembi Ngubane, then 19, kept an audio diary, chronicling her life with AIDS. Her audio diary was broadcast on NPR on All Things Considered. Over the course of a year, Thembi recorded about 50 hours of tape.

According to results of the GRACE (Gender, Race, And Clinical Experience) study, presented on July 20, 2009 at the 5th International AIDS Society Conference on HIV Pathogenesis, Treatment, and Prevention (IAS 2009) in Cape Town, South Africa, it is possible to recruit a large number of women, African Americans, and Latinos into U.S. based HIV treatment studies. GRACE is the largest study to date in treatment-experienced adult women with HIV to determine gender and race differences in response to an HIV therapy -- ritonavir-boosted darunavir (Prezista/r) -- as part of combination therapy. The study demonstrated that through 48 weeks of therapy, there were no statistically significant differences in virologic response rates between treatment-experienced women and men receiving the protease inhibitor PREZISTA (600 mg twice daily with 100 mg ritonavir), with a background regimen. In addition, there were no clinically relevant gender-based differences in adverse events.

Fourteen U.S. organizations working on issues related to human rights, women, and HIV/AIDS submitted a series of policy recommendations to guide the Office of National AIDS Policy and related agencies in their efforts to achieve better outcomes for women living with and affected by HIV. The report, entitled, "Critical Issues for Women and HIV: Health Policy and the Development of a National AIDS Strategy" calls attention to the factors contributing to the disproportionate rates of HIV among low-income women and women of color, as well as poor outcomes for women living with HIV, and proposes concrete solutions that integrate systems of prevention and delivery of care.

Female Health Company's second-generation female condom, FC2, becomes available in the United States. This cheaper, quieter, more acceptable alternative to the earlier FC1 gives women a new option in taking control of HIV prevention.

The White House Office of National AIDS Policy (ONAP) holds a historic meeting focused on women and HIV.

More From This Resource Center

Newly Diagnosed? Words of Encouragement from HIV-Positive Women

What Every HIV-Positive Woman Should Know About GYN Care and Prevention

This article was provided by Terri Wilder. It is a part of the publication A Timeline of Women Living With HIV: Past, Present and Future.


The content on this page is free of advertiser influence and was produced by our editorial team. See our advertising policy.

See Also
Newly Diagnosed? Words of Encouragement from HIV-Positive Women
What Did You Expect While You Were Expecting?
HIV Tools You Can Use